Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME of [14C]SHR0302 in Healthy Chinese Males
NCT05047341Phase 1Completed
- Sponsor
- Hengrui
- Start
- Sep 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ivarmacitinib in rheumatoid arthritis (RA), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last measurable concentration and 5 more. Started Sep 2021; status: completed.
02
Drugs
ivarmacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05047341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05047341.